These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 8680052)

  • 1. Mycophenolate mofetil in liver transplantation.
    McDiarmid SV
    Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
    Hebert MF; Ascher NL; Lake JR; Emond J; Nikolai B; Linna TJ; Roberts JP
    Transplantation; 1999 Mar; 67(5):707-12. PubMed ID: 10096526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
    Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
    Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
    Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
    Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
    Vasquez EM; Sifontis NM; Pollak R; Benedetti E
    Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
    Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT
    Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.